NEWS | alsv

Companies in the News

Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study

10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike...

Generate:Biomedicines Announces Close of $273M Series C Financing

Funding will advance pipeline of 17 existing programs and approximately 10 new starts annually Company has raised nearly $700 million in...

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc....

EBR Systems' Pivotal SOLVE-CRT Trial Meets Endpoints: Excellent Interim Analysis Results

Data Presented at Late-Breaking Session at Heart Rhythm Society 2023: Paves Way for Premarket Approval Application for Federal Drug...

Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement

Multi-year collaboration will facilitate the co-development of optimized therapeutics that bind to challenging targets in ways...

Sana Biotechnology Announces Preclinical Data Published in Nature Communications

Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic...

Ring Therapeutics Raises $86.5M in Series C Funding to Create Next Generation Programmable Medicines

Ring raised a total of $86.5 million from new and returning investors, validating its unique approach to creating next-generation...

Aera Therapeutics Launches with $193 M for the Next Generation of Transformative Genetic Medicines

Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range...

Tessera Therapeutics Highlights Advancements Across its Gene Writing™ and Delivery Platforms

RNA Gene Writing™ platform demonstrates clinically relevant levels of in vivo rewriting in the genome of liver cells of non-human...